GlassScriptPhysician profile
Ryan Matthew Orgel
NPI 1013336015
$4,178.02
in general payments reported to CMS, 2019-2025
31 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $253 · 2021: $122 · 2022: $245 · 2023: $582 · 2024: $1,644 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,558.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $502.46 | 2023-2025 | Lifevest |
| Abbott Laboratories | $440.66 | 2020-2025 | Diamondback Coronary, Optis |
| Inari Medical, INC. | $406.27 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $375.82 | 2024-2025 | Avvigo Guidance System, Opticross, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $350.33 | 2020-2025 | Farxiga, Wainua |
| Pfizer INC. | $278.40 | 2024-2025 | |
| Abiomed | $268.67 | 2020-2025 | Impella |
| Irhythm Technologies, INC. | $239.73 | 2024 | Zio Monitor, Zio Xt Patch |
| Shockwave Medical, INC | $156.87 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $125.76 | 2023-2025 | (Br4) Coronary Undivided, Extended Holter, (Br3) Coronary Other |
| Medtronic, INC. | $116.55 | 2021-2025 | Corevalve Evolut R |
| Heartflow, INC. | $114.44 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $113.39 | 2023-2025 | |
| Imperative Care, INC | $110.11 | 2025 | Symphony Catheter |
| Esperion Therapeutics, INC. | $77.76 | 2024-2025 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $69.56 | 2025 | Flowtriever |
| Amgen INC. | $56.29 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $48.28 | 2024-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.77 | 2024-2025 | Jardiance |
| Terumo Medical Corporation | $35.90 | 2024-2025 | Angio-Seal, Glidewire, Heartrail |
| Alnylam Pharmaceuticals INC. | $34.87 | 2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $33.42 | 2024 | |
| Janssen Pharmaceuticals, INC | $28.97 | 2023-2024 | Xarelto |
| Genzyme Corporation | $28.36 | 2024 | |
| Impulse Dynamics (USA) INC. | $26.89 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $23.39 | 2023 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $22.71 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $18.11 | 2025 | Camzyos |
| Kestra Medical Technology Services, INC. | $14.16 | 2023 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $14.04 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $5.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Orgel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.